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The central nervous system (CNS) is considered an immune-privileged tissue protected
by a specific vessel structure, the blood-brain barrier (BBB). Upon infection or traumatic
injury in the CNS, the BBB is breached, and various immune cells are recruited to the
affected area. In the case of autoimmune diseases in the CNS like multiple sclerosis
(MS), autoreactive T cells against some CNS-specific antigens can theoretically attack
neurons throughout the CNS. The affected CNS regions in MS patients can be detected as
multiple focal plaques in the cerebrum, thoracic cord, and other regions. Vision problems
are often associated with the initial phase of MS, suggesting a disturbance in the optic
nerves. These observations raise the possibility that there exist specific signals that direct
autoreactive T cells past the BBB and into particular sites of the CNS. Using a mouse
model of MS, experimental autoimmune encephalomyelitis (EAE), we recently defined the
mechanism of the pathogenesis in which regional neural stimulations modulate the status
of the blood vessel endothelium to allow the invasion of autoreactive T cells into specific
sites of the CNS via the fifth lumbar cord. This gate for autoreactive T cells can be artificially
manipulated by removing gravity forces on the hind legs or by electric pulses to the soleus
muscles, quadriceps, and triceps of mice, resulting in an accumulation of autoreactive T
cells in the intended regions via the activation of regional neurons. Gating blood vessels
by regional neural stimulations, a phenomenon we call the gateway theory, has potential
therapeutic value not only in preventing autoimmunity, but also in augmenting the effects
of cancer immunotherapies.
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INTRODUCTION
The immune system is a sophisticated protective mechanism that
coordinates many types of bone-marrow derived hematopoietic
cells including T cells, B cells, dendritic cells, and macrophages
among others that have evolved to combat infectious agents
and cancerous cells in the body. Careful regulation is required
to control the immune system, because uncontrollable immune
reactions, or chronic inflammation, are harmful and considered
the pathogenesis of many diseases. It has been long recognized yet
not well elucidated that neural activation directly influences the
immune system. For example, mentally ill stresses in mice pro-
mote tumor progression, while good stresses, or eustress, which
are induced by an enriched housing environment with increased
space, physical activity, and social interactions, suppress it (Cao
et al., 2010; Feng et al., 2012; Hassan et al., 2013). In human
patients with autoimmune diseases, it has been suggested that
psychological stresses including depression and anxiety are asso-
ciated with disease progression and relapse (Mitsonis et al., 2009;
Srivastava and Boyer, 2010). Whereas systemic modulation of
the immune system by the nervous system through the secre-
tion of corticosteroid is relatively well characterized, the regional
interplay between these two biological systems is just beginning
to be elucidated. Here we discuss the regional neuro-immune
interactions during chronic inflammations including our recent
findings.
INFLAMMATION UNDERLIES MANY TYPES OF
CHRONIC DISEASES
Traditionally, inflammation has been defined as pathophysiologi-
cal symptoms with dolor, calor, rubor, and tumor (Latin for pain,
heat, redness, and swelling, respectively). We now know that these
symptoms are the consequences of the local accumulation and
activation of immune cells that produce soluble factors such as
cytokines and lipid mediators. Therefore, it is not an oversimpli-
fication to define inflammation as a biological mechanism that
locally recruits various immune cells followed by the disruption of
local homeostasis. Inflammation, or the accumulation of immune
cells, basically acts as a protective mechanism against infectious
agents including viruses and bacteria. In fact, mice genetically
lacking T lymphocytes, which secrete various cytokines to orches-
trate the immune reactions (CD4+ helper T cells) and exert
cytotoxic activities that kill unnecessary or undesirable cells, such
as infected cells as well as cancer cells (CD8+ killer T cells), are
unable to control pathogen invasion via inflammation induction.
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At the same time, inflammation has to resolve immediately after
these incidences come to an end, since chronically persistent
inflammation has a rather adverse effect. Autoimmune diseases
such as rheumatoid arthritis (RA) and multiple sclerosis (MS)
are good examples of diseases that involve chronic inflammation.
Signs of inflammation (i.e., local accumulation of immune cells
followed by dysregulation of local homeostasis) are evident in
the joints and the central nervous system (CNS) of RA and MS
patients, respectively. We have also found the similar phenom-
ena in the target organs of animal models for these diseases. In
addition, accumulating evidence indicates that chronic inflam-
mation underlies the pathogenesis of many other types of disor-
ders including neurodegenerative diseases, metabolic syndromes,
and even psychiatric diseases (Hamdani et al., 2012; Tabas and
Glass, 2013). Thus, understanding the molecular mechanisms
that convert protective acute inflammation into harmful chronic
inflammation and how chronic inflammation persists is essential
to the development of novel therapeutic interventions for many
diseases and disorders.
THE INFLAMMATION AMPLIFIER PROVIDES A MOLECULAR
MECHANISM FOR CHRONIC INFLAMMATION
ESTABLISHMENT OF A RHEUMATOID ARTHRITIS MODEL, F759 MICE
Interleukin (IL)-6 is a well-studied cytokine that promotes
inflammation. In fact, IL-6 is found upregulated in the serum and
affected areas of human diseases and disorders such as synovial
fluids in the case of RA, while genome-wide association studies
(GWAS) have revealed that the IL-6 gene is genetically associated
with a wide range of diseases including autoimmunity, neurode-
generative diseases, and cancer (http://geneticassociationdb.nih.
gov/). Therefore, the establishment of an IL-6-dependent disease
model has been desired for understanding the pathogenesis of
various inflammatory diseases. IL-6 signals emanating from IL-
6 receptor complexes, gp130 and IL-6R, involve the activation
of STAT3, the central transcription factor for the many biolog-
ical effects of IL-6. SOCS3 is a target gene of IL-6 and known
to negatively regulate the signal transduction of IL-6 by bind-
ing to the receptor subunit gp130 and Jak kinases (Kamimura
et al., 2003; Murakami et al., 2004). Given that IL-6 is abun-
dant in patients with inflammatory disorders, we hypothesized
that persistent activation of IL-6/gp130 signaling might induce
inflammatory diseases. We therefore generated a knock-in mouse
with a point mutation at the binding site of SOCS3 in gp130,
thereby enhancing the IL-6 signal pathway (Ohtani et al., 2000).
As expected, this mouse strain, called F759mice, develops RA-like
joint diseases spontaneously (Atsumi et al., 2002).
DISCOVERY OF THE INFLAMMATION AMPLIFIER
Breeding experiments with various deficient mouse strains
showed the joint disease in F759 mice mainly relies on CD4+
T cells, IL-6, and IL-17, which is a recently reported helper
T-cell-derived cytokine involved in autoimmunity and activa-
tion of the transcription factor NF-κB (Sawa et al., 2006; Ogura
et al., 2008). Indeed, the number of an IL-17-secreting CD4+
T cell subtype (Th17 cells) and the serum levels of IL-17 were
increased in F759 mice. Furthermore, systemic expressions of
IL-17 or IL-6 in F759 mice accelerated the disease onset and,
interestingly, induced the production of IL-6 itself, suggesting
a positive feedback loop (Ogura et al., 2008). Moreover, IL-17
expression in F759 mice induced an excessive level of IL-6 and
chemokines. In vitro experiments using fibroblasts confirmed that
IL-6 is a target of the simultaneous treatment of IL-17 and IL-
6, but not of either cytokine alone (Ogura et al., 2008). DNA
microarray analysis revealed that many chemokines are also tar-
gets of this synergism. Since chemokines recruit immune cells
to promote inflammation via the dysregulation of local home-
ostasis, we named this synergistic mechanism the inflamma-
tion amplifier (formerly, IL-6 amplifier) (Figure 1) (Murakami
and Hirano, 2012). Activation of the inflammation amplifier
in endothelial cells is induced by the simultaneous activation
of NF-κB and STAT3 followed by chemokine expressions. We
expected that NF-κB and STAT3 stimulants, whether they are pro-
inflammatory or anti-inflammatory cytokines, should enhance
the expression of the chemokines. However, anti-inflammatory
cytokines might indirectly suppress the activation of the inflam-
mation amplifier by inhibiting activated helper T cells, which
express various NF-κB and STAT3 stimulants including IL-
17, IL-6, and TNFα. Moreover, as discussed in detail below,
the inflammation amplifier, which can be regulated by neural
inputs such as norepinephrine (NE), enhances the production
of chemokines via NF-κB activation (Figure 1) (Arima et al.,
2012).
FIGURE 1 | The inflammation amplifier. (A) Image of the activation of the
inflammation amplifier in the presence and absence of NE. A combination
of IL-17 and IL-6 causes a synergistic effect on the induction of
inflammation-amplifier target chemokines such as CCL20 in non-immune
cells including fibroblasts, endothelial cells, and certain synovial cells. NE
further enhances the chemokine production. Other neurotransmitters can
also influence activation of the inflammation amplifier. See Arima et al.
(2012) for the original data. (B) The synergistic effect seen in (A) requires
the concomitant activation of two transcriptions factors, NF-kB and STAT3.
In the case of autoimmune diseases, Th-17 derived IL-17 induces an initially
low amount of IL-6 from non-immune cells via NF-κB activation. Secreted
IL-6 together with IL-17 forms a positive feedback loop to produce
excessive expression of the target genes including many inflammatory
chemokines such as CCL20, CCL2, etc. Consequently, various immune
cells are recruited at the region around the target cells via chemokine
expression, and inflammation takes place. Persistent activation of the
inflammation amplifier, as is the case in F759 mice, drives chronic
inflammation. IL-7, a target of the amplifier and derived from non-immune
cells, fuels the proliferation, and survival of Th17 cells. The activation of the
inflammation amplifier can be modulated by regional neural activation.
Frontiers in Neuroscience | Neuroendocrine Science October 2013 | Volume 7 | Article 204 | 2
Kamimura et al. The gateway theory between neural and immune systems
THE INFLAMMATION AMPLIFIER IS ASSOCIATED WITH VARIOUS
HUMAN DISEASES AND DISORDERS
Mice deficient in gp130 or STAT3 in fibroblasts and/or endothelial
cells (i.e., inflammation amplifier-defective non-immune cells)
are highly resistant to animal disease models including RA, MS,
and allogeneic graft rejection, demonstrating that the inflam-
mation amplifier is critical for multiple chronic inflammatory
diseases in vivo (Ogura et al., 2008; Murakami et al., 2011; Arima
et al., 2012; Lee et al., 2012). To explore the molecular mecha-
nisms underlying the inflammation amplifier, we recently con-
ducted genome-wide functional screening and identified around
1700 candidates that positively regulate it.
Interestingly, genes associated with human diseases including
not only autoimmunity, but also metabolic syndromes, neurode-
generative diseases, and other inflammatory diseases including
allergies and atopic dermatitis were significantly enriched in the
candidate genes (Murakami et al., 2013). Based on these findings,
we propose that de novomutations, expression alterations, or epi-
genetic changes of these genes in non-immune cells during acute
inflammation can cause dysregulation of the amplifier like that
observed in F759 mice (i.e., a point-mutation of gp130), turning
acute inflammation into a pathogenic chronic version.
NEURO-IMMUNE INTERACTIONS MEDIATE IMMUNE
HOMEOSTASIS AND PATHOGENESIS
AUTOREACTIVE CD4+ T CELLS ENTER THE CNS FROM THE FIFTH
LUMBAR CORD
MS is a chronic inflammatory disease in the CNS that, accord-
ing to a recent genome-wide association study, involves CD4+
T cells (International Multiple Sclerosis Genetics et al., 2011). An
animal model of MS, experimental autoimmune encephalomyeli-
tis (EAE), is widely used to study the pathogenesis of MS, and
autoreactive CD4+ T cells, in particular Th17 cells, have been
demonstrated to be essential for the disease induction (Komiyama
et al., 2006). In these experiments, mice or rats were immunized
with CNS antigens such as myelin oligodendrocyte glycopro-
tein (MOG) or a proteolipid protein, resulting in the genera-
tion of autoreactive CD4+ T cells that target the CNS and the
development of MS-like symptoms including progressive paral-
ysis, particularly in the lower body. EAE can also be induced
by a passive transfer method that is performed via the intra-
venous transfer of these autoreactive CD4+ T cells into naïve
recipient animals. Indeed, the passive transfer method is suit-
able to track the behavior of the disease-causing CD4+ T cells
without affecting the immune system systemically by adjuvant
treatment. We have shown using the transfer method-induced
EAE that the inflammation amplifier is critically involved in
EAE development, because the disease symptoms were signif-
icantly ameliorated in amplifier-deficient mice such as type-1
collagen cre/gp130flox mice (Ogura et al., 2008; Arima et al.,
2012). These results challenge traditional theories, because the
blood-brain barrier (BBB) should block the migration of the
pathogenic CD4+ T cells into the CNS. We thus sought the ini-
tial site where autoreactive CD4+ T cells invade the CNS during
the development of EAE. A clinical symptom of typical EAE con-
stantly begins with a loss of tonicity in the tail tip, suggesting
immune attacks at a particular site in the lower body despite the
uniform presence of the autoantigens in the CNS. Whole-mount
sections of adult mice at a preclinical stage of EAE revealed that
MOG-reactive CD4+ T cells preferentially entered the CNS from
the dorsal vessels of the fifth lumbar (L5) cord (Arima et al.,
2012).
DORSAL VESSELS OF THE L5 CORD EXPRESS VARIOUS CHEMOKINES
VIA ACTIVATION OF THE INFLAMMATION AMPLIFIER, EVEN AT
STEADY STATE
This accumulation of CD4+ T cells is dependent on the inflam-
mation amplifier, as expected. In addition, the treatment of mice
with antibodies against CCL20, a chemokine potently recruiting
Th17 and a target gene of the inflammation amplifier, suppressed
the CD4+ T cell accumulation at the L5 dorsal vessels, suggest-
ing that amplifier-mediated CCL20 overproduction causes the
recruitment of pathogenic Th17 at the L5 cord (Arima et al.,
2012). In fact, not only CCL20, but also various chemokines were
upregulated at L5 dorsal vessels during EAE as compared to dorsal
vessels from the other spinal levels. Unexpectedly, the upreg-
ulation of chemokines at L5 vessels was observed even under
steady state (i.e., the natural condition). Given that a certain
number of immune cells are present in the CNS, probably for
the purpose of immune surveillance, and that the CNS-resident
microglia is of bone-marrow origin, the increase of chemokines
at the L5 cord may function as a gate for their precursors from
the periphery to the CNS, although further studies are needed to
confirm this conclusion.
REGIONAL NEURAL ACTIVATION INDUCED BY GRAVITY PLAYS A ROLE
IN CHEMOKINE EXPRESSION AT THE L5 GATE
Why the L5 is the location of the gate was answered by inves-
tigating a neuro-immune interaction. It is known that sensory
neurons in the dorsal root ganglion (DRG) beside the L5 cord are
connected to the soleus muscles, the main anti-gravity muscles
(Ohira et al., 2004). We considered whether constant stimu-
lation of the soleus muscles by a gravity force might mediate
entry of the MOG-specific Th17 cells at the L5 cord. Indeed,
when mice were tail-suspended so that the hind limbs were
released from the gravity stimuli (Figure 2), MOG-specific Th17
cells no longer accumulated at the L5 cord. Instead, these Th17
FIGURE 2 | Effects of regional neural activation on the invasion of Th17
cells into the CNS. Tail suspension and electric stimulation of the soleus
muscles (left). Tail suspension (TS) reduces CCL20 expression in the L5
dorsal vessel. Electric stimulations (ES) to the soleus muscles of TS mice
restore the chemokine expression in a time-dependent manner (right). See
Arima et al. (2012) for the original data.
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cells accumulated at cervical cords as if a new gate was opened
by a gravitational burden on the fore limb muscles (Arima
et al., 2012). Consistently, the tail suspension suppressed CCL20
mRNA expression in the L5 dorsal blood vessels and decreased
the expression of the neural activation marker c-fos in the
L5 DRG. Moreover, artificial electric stimulations to the soleus
muscles of the tail-suspended mice restored CCL20 expression
(Figure 2) and Th17 accumulation at the L5 cord, as well as
c-fos levels in the L5 DRG (Arima et al., 2012). These results
strongly suggest that neural inputs from the soleus muscles
in response to the gravity force play a role in activating the
inflammation amplifier and lead to the expression of various
chemokines including Th17-attracting CCL20 in L5 dorsal blood
vessels.
A SENSORY-SYMPATHETIC INTERACTION IS CRITICAL FOR THE L5
ENTRY OF THE AUTOREACTIVE T CELLS
What mechanisms do afferent sensory neurons from the soleus
muscles use to regulate the status of blood vessels at L5? Although
a precise neural network remains elusive, we have shown sympa-
thetic nerves to be involved. Blood flow speeds at L5 dorsal vessels
become slower when mice are tail suspended, while electronic
stimulation of the soleus muscles increases the flow speed. These
results clearly suggest that autonomic nerves including sympa-
thetic neurons are involved in the response to the tail suspension.
In addition, blood flow speeds in blood vessels other than the L5
region, such as the femoral vessels, brain surface vessels, and the
portal vein, are not affected by tail suspension (Arima et al., 2012).
Furthermore, treatment with atenolol, a β1 adrenergic receptor
antagonist, or prazosin, an α1 adrenergic receptor antagonist,
significantly inhibits CCL20 mRNA expression, NF-κB mRNA
expression, and MOG-reactive Th17 accumulation at L5 vessels
and also suppresses clinical signs of EAE (Arima et al., 2012).
Consistent with these in vivo results, the addition of NE, which
is a neurotransmitter from sympathetic neurons, to a culture of
endothelial cells enhances chemokine expressions mediated by
the activation of the inflammation amplifier (Figure 1A). Thus,
anti-gravity responses of the soleus muscles lead to sympathetic
nerve stimulation, creating a gateway for immune cells to pass
through the CNS via L5 dorsal vessels (Arima et al., 2012). Based
on these findings, we concluded that MOG-reactive, disease-
causing Th17 cells make use of the L5 gateway to infiltrate the
CNS and induce local inflammation by producing cytokines like
IL-17 and IL-6, which further induces chemokines via the inflam-
mation amplifier in parenchymal non-immune cells and results
in chronic inflammation in the CNS (Figure 3). Thus, the neu-
ral response triggered by the gravity force creates a gate for
immune cells to invade the CNS, although we also hypothe-
size that the clearance and/or apoptosis of immune cells in the
CNS may contribute to the feed-forward mechanism of contin-
ued neuroinflammation (Goldmann et al., 2006). Our findings
also imply that various types of neural activity affect the disease
status differently. Indeed, we found and are currently studying
the mechanism for how certain physical or mental stresses cause
the deterioration or relapse of EAE in mice, which will shed new
light on the molecular mechanism of the relapse and remission
of MS.
THE GATEWAY THEORY
Neuronal innervation occurs throughout the body and appropri-
ately controls all organs. One potential strategy to therapeutically
manage neuro-immune interactions is to find and stimulate the
appropriate peripheral neurons connected to the organs to be
treated. To test this theory, we selectively stimulated sensory neu-
rons via electric stimulations of different muscles and observed
local chemokine expressions in the vessels of spinal cords as a
FIGURE 3 | Gateway for autoreactive T cells into the CNS. Continuous
stimulation of the soleus muscles by gravity leads to the constant activation
of L5 DRG sensory neurons, followed by the activation of sympathetic
neurons at the L5 region via unidentified circuits (?). NE, a neurotransmitter
from sympathetic neurons, augments the inflammation amplifier at the
dorsal vessels of L5, causing an elevation of CCL20 and subsequent Th17
infiltration into the CNS.
FIGURE 4 | The gateway theory. Electric pulses to the upper arm, thigh,
and soleus muscles induce activation of the inflammation amplifier
(chemokine upregulation), thereby opening a gate in the dorsal vessels of
the fifth cervical to fifth thoracic (C5-T5), third lumbar (L3), and fifth lumbar
(L5) cords, respectively. Environmental stresses such as those from social
interactions and mental stresses might create a specific gate in the brain.
This effect is potentially an attractive target for manipulating immune cell
migration in vivo.
Frontiers in Neuroscience | Neuroendocrine Science October 2013 | Volume 7 | Article 204 | 4
Kamimura et al. The gateway theory between neural and immune systems
marker of the inflammatory response. Thigh muscles including
the quadriceps are known to be regulated by L3 DRG neurons.
Interestingly, electronic stimulation of these muscles followed
by L3 DRG activation led to an increased expression of CCL20
in the L3 cord dorsal vessels of mice (Arima et al., 2012). In
a similar fashion, chemokine levels in the fifth cervical to fifth
thoracic cord vessels were upregulated by stimulations of the
epitrochlearis/triceps brachii and upper arm muscles, are con-
trolled by neurons located at the corresponding areas (Figure 4)
(Arima et al., 2012). Based on these results, we propose “the
gateway theory,” which describes blood vessels that act as gates
for immune cell infiltration into organs and is dependent on
regional neural stimulations. The theory is supported by empiri-
cal evidence that shows stresses from environments can affect the
disease status and trigger relapse in MS patients. Experimentally,
we have found that certain environmental stresses influence the
disease progression in EAEmice by creating gates for autoreactive
helper T cells to enter the CNS (manuscript in preparation). We
hypothesize that these stresses create gates at certain CNS vessels
via neural control of the inflammation amplifier to modify the
disease status at specific vessels (Figure 4).
FUTURE DIRECTIONS
Investigations on whether the gateway theory can be more gen-
erally applied to tissues beyond the CNS are currently ongoing.
If true, artificial manipulation of the gate should have signifi-
cant clinical benefits, as closing it in normal cells would dampen
autoimmune inflammation in a target organ without any sys-
temic immune suppression, while opening it in tumors could
enhance cancer immunotherapy. The precise molecular mecha-
nisms for gating still need to be studied, however, to confirm this
possibility.
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